Atlas Trials

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

Clinical trial NCT06059469 · RECRUITING

Trial details

NCT number
NCT06059469
Sponsor
Jules Bordet Institute
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
TNBC - Triple-Negative Breast Cancer
Start date
2022-05-30
Primary completion
2025-06-02
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.